NASDAQ:MCRB Seres Therapeutics (MCRB) Stock Price, News & Analysis → Dems have chosen Biden replacement? (From Paradigm Press) (Ad) Free MCRB Stock Alerts $1.11 +0.03 (+2.78%) (As of 05/2/2024 ET) Add Compare Share Share Today's Range$1.00▼$1.1150-Day Range$0.56▼$1.2352-Week Range$0.54▼$6.26Volume3.23 million shsAverage Volume4.79 million shsMarket Capitalization$167.62 millionP/E RatioN/ADividend YieldN/APrice Target$6.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Seres Therapeutics alerts: Email Address Seres Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside485.6% Upside$6.50 Price TargetShort InterestHealthy11.67% of Shares Sold ShortDividend StrengthN/ASustainability-1.14Upright™ Environmental ScoreNews SentimentN/AInsider TradingSelling Shares$20,371 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.15) to ($0.84) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.17 out of 5 starsMedical Sector160th out of 908 stocksBiotechnology Industry1st out of 19 stocks 3.5 Analyst's Opinion Consensus RatingSeres Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageSeres Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted11.67% of the outstanding shares of Seres Therapeutics have been sold short.Short Interest Ratio / Days to CoverSeres Therapeutics has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in Seres Therapeutics has recently decreased by 6.22%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSeres Therapeutics does not currently pay a dividend.Dividend GrowthSeres Therapeutics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSeres Therapeutics has received a 71.59% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for infectious diseases", "Clinical research services for physiological diseases ", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Seres Therapeutics is -1.14. Previous Next 2.4 News and Social Media Coverage News SentimentSeres Therapeutics has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Seres Therapeutics this week, compared to 1 article on an average week.Search Interest25 people have searched for MCRB on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.MarketBeat Follows10 people have added Seres Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 11% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Seres Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $20,371.00 in company stock.Percentage Held by InsidersOnly 5.10% of the stock of Seres Therapeutics is held by insiders.Percentage Held by Institutions59.34% of the stock of Seres Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Seres Therapeutics are expected to grow in the coming year, from ($1.15) to ($0.84) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Seres Therapeutics is -1.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Seres Therapeutics is -1.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad The Freeport SocietyBiden Nomination CANCELED?The Hill just published that Joe Biden has received enough delegates to…“clinch the Democratic presidential nomination and all but guaranteeing he will face off against former President Trump again in November.” Why is he all BUT guaranteed the Democratic nomination, in their words?I believe I have the terrifying answer right here. About Seres Therapeutics Stock (NASDAQ:MCRB)Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.Read More MCRB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MCRB Stock News HeadlinesApril 30, 2024 | money.usnews.comSeres Therapeutics IncApril 9, 2024 | businesswire.comSeres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCTMay 2, 2024 | Stansberry Research (Ad)The Long-Awaited End of America UpdateA 995% Gain Last Time We Shared this "Election Secret" It's a straightforward way to come out on top no matter who wins this November… It's not cryptos, or options, and anyone can do it.March 28, 2024 | finance.yahoo.comIncreases to Seres Therapeutics, Inc.'s (NASDAQ:MCRB) CEO Compensation Might Cool off for nowMarch 11, 2024 | finance.yahoo.comMCRB Apr 2024 1.000 putMarch 7, 2024 | finance.yahoo.comSeres Therapeutics, Inc. (NASDAQ:MCRB) Q4 2023 Earnings Call TranscriptMarch 6, 2024 | realmoney.thestreet.comSeres Therapeutics price target lowered by $4 at Oppenheimer, here's whyMarch 6, 2024 | markets.businessinsider.comSeres Therapeutics (MCRB) Gets a Buy from TD CowenMay 2, 2024 | Stansberry Research (Ad)The Long-Awaited End of America UpdateA 995% Gain Last Time We Shared this "Election Secret" It's a straightforward way to come out on top no matter who wins this November… It's not cryptos, or options, and anyone can do it.March 6, 2024 | finance.yahoo.comQ4 2023 Seres Therapeutics Inc Earnings CallMarch 5, 2024 | investorplace.comMCRB Stock Earnings: Seres Therapeutics Beats EPS for Q4 2023March 5, 2024 | investorplace.comGold Price Alert: Gold Spot Prices Just Hit a Record High TodayMarch 5, 2024 | msn.comSeres Therapeutics GAAP EPS of -$0.89 beats by $0.10, revenue of $126.33M beats by $0.23MMarch 5, 2024 | finance.yahoo.comSeres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdatesMarch 5, 2024 | finance.yahoo.comSeres Therapeutics Inc (MCRB) Reports Encouraging Sales Growth and Strategic Cost Savings in 2023March 4, 2024 | benzinga.comSeres Therapeutics's Earnings: A PreviewMarch 2, 2024 | morningstar.comSeres Therapeutics Inc MCRBFebruary 28, 2024 | businesswire.comSeres Therapeutics to Host Fourth Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on March 5, 2024February 27, 2024 | finance.yahoo.comSeres Therapeutics to Participate in Cowen 44th Annual Healthcare ConferenceFebruary 27, 2024 | businesswire.comSeres Therapeutics to Participate in Cowen 44th Annual Healthcare ConferenceFebruary 26, 2024 | markets.businessinsider.comSeres Therapeutics Appoints Marella Thorell As New CFO Following Retirement Of David ArkowitzFebruary 26, 2024 | finance.yahoo.comSeres Therapeutics Announces the Appointment of Marella Thorell as Chief Financial Officer and the Retirement of David ArkowitzFebruary 26, 2024 | businesswire.comSeres Therapeutics Announces the Appointment of Marella Thorell as Chief Financial Officer and the Retirement of David ArkowitzFebruary 22, 2024 | benzinga.comSeres Therapeutics Stock (NASDAQ:MCRB), Short Interest ReportFebruary 18, 2024 | msn.comNew Seres 3 arrives in the UK priced from £29,995February 18, 2024 | msn.comMeet the UK's cheapest new electric SUV: the new Seres 3, yours for just under £30kFebruary 7, 2024 | markets.businessinsider.comSell Rating on Seres Therapeutics Amid Underperforming Sales and Financial ChallengesSee More Headlines Receive MCRB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Seres Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/05/2024Today5/02/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:MCRB CUSIPN/A CIK1609809 Webwww.serestherapeutics.com Phone(617) 945-9626FaxN/AEmployees233Year FoundedN/APrice Target and Rating Average Stock Price Target$6.50 High Stock Price Target$8.00 Low Stock Price Target$5.00 Potential Upside/Downside+485.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.90) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-113,720,000.00 Net MarginsN/A Pretax Margin-90.03% Return on EquityN/A Return on Assets-32.43% Debt Debt-to-Equity RatioN/A Current Ratio1.78 Quick Ratio1.48 Sales & Book Value Annual Sales$126.32 million Price / Sales1.33 Cash FlowN/A Price / Cash FlowN/A Book Value($0.35) per share Price / Book-3.17Miscellaneous Outstanding Shares151,010,000Free Float143,308,000Market Cap$167.62 million OptionableOptionable Beta2.16 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Eric D. Shaff M.B.A. (Age 48)President, CEO & Director Comp: $1.02MDr. Lisa von Moltke M.D. (Age 65)Executive VP & Chief Medical Officer Comp: $725.15kDr. Teresa L. Young Ph.D. (Age 57)R.Ph., Executive VP and Chief Commercial & Strategy Officer Comp: $606.33kMs. Marella Thorell (Age 57)Executive VP & CFO Dr. David S. Ege Ph.D. (Age 49)Executive VP & Chief Technology Officer Comp: $142.71kDr. Matthew R. Henn Ph.D. (Age 49)Executive VP & Chief Scientific Officer Comp: $643.83kMr. Carlo Tanzi Ph.D.Investor Relations OfficerMr. Thomas J. DesRosier Esq. (Age 69)J.D., Chief Legal Officer, Executive VP & Secretary Comp: $719.55kMs. Caroline HoldaAssistant General CounselMore ExecutivesKey CompetitorsCervoMedNASDAQ:CRVORegulus TherapeuticsNASDAQ:RGLSAEON BiopharmaNASDAQ:AEONSyros PharmaceuticalsNASDAQ:SYRSI-MabNASDAQ:IMABView All CompetitorsInsiders & InstitutionsMirae Asset Global Investments Co. Ltd.Bought 50,102 shares on 5/1/2024Ownership: 0.033%BNP Paribas Financial MarketsSold 11,496 shares on 5/1/2024Ownership: 0.031%David ArkowitzSold 3,939 sharesTotal: $4,254.12 ($1.08/share)Eric D ShaffSold 11,549 sharesTotal: $12,472.92 ($1.08/share)Teresa L YoungSold 3,374 sharesTotal: $3,643.92 ($1.08/share)View All Insider TransactionsView All Institutional Transactions MCRB Stock Analysis - Frequently Asked Questions Should I buy or sell Seres Therapeutics stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Seres Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MCRB shares. View MCRB analyst ratings or view top-rated stocks. What is Seres Therapeutics' stock price target for 2024? 2 brokers have issued twelve-month price targets for Seres Therapeutics' stock. Their MCRB share price targets range from $5.00 to $8.00. On average, they expect the company's share price to reach $6.50 in the next year. This suggests a possible upside of 485.6% from the stock's current price. View analysts price targets for MCRB or view top-rated stocks among Wall Street analysts. How have MCRB shares performed in 2024? Seres Therapeutics' stock was trading at $1.40 at the beginning of the year. Since then, MCRB stock has decreased by 20.7% and is now trading at $1.11. View the best growth stocks for 2024 here. When is Seres Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our MCRB earnings forecast. How were Seres Therapeutics' earnings last quarter? Seres Therapeutics, Inc. (NASDAQ:MCRB) announced its earnings results on Tuesday, March, 5th. The biotechnology company reported ($0.32) earnings per share for the quarter, topping analysts' consensus estimates of ($0.40) by $0.08. The biotechnology company earned $0.06 million during the quarter, compared to the consensus estimate of $0.50 million. What other stocks do shareholders of Seres Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Seres Therapeutics investors own include OPKO Health (OPK), TherapeuticsMD (TXMD), Juno Therapeutics (JUNO), NVIDIA (NVDA), Walt Disney (DIS), Alibaba Group (BABA), Novavax (NVAX), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX) and Gilead Sciences (GILD). When did Seres Therapeutics IPO? Seres Therapeutics (MCRB) raised $101 million in an IPO on Friday, June 26th 2015. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and BofA Merrill Lynch served as the underwriters for the IPO and Leerink Partners and Canaccord Genuity were co-managers. Who are Seres Therapeutics' major shareholders? Seres Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Mirae Asset Global Investments Co. Ltd. (0.03%) and BNP Paribas Financial Markets (0.03%). Insiders that own company stock include David Arkowitz, David S Ege, Eric D Shaff, Health Ltp Fund Ge Nutritional, Paula Cloghessy, Teresa L Young and Thomas Desrosier. View institutional ownership trends. How do I buy shares of Seres Therapeutics? Shares of MCRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MCRB) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersCould Your Accounts Be Frozen?Allegiance GoldUrgent Nvidia WarningAltimetryBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingNew Trump BombshellThe Freeport SocietyTruth about Trump you’ve never heardPorter & CompanyHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Seres Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
